ARENSIA Exploratory Medicine is a German company entirely specialized to address a strategic market niche, namely the high need for FAST PATIENT RECRUITMENT in Phase I / II / PROOF OF CONCEPT clinical trials.The projects are performed in own, modern Phase I units, which are located in large hospitals in Eastern Europe.
ARENSIA brings together large patient populations, incl. treatment/ biological naïve, with yearlong know-how in exploratory clinical trials. The combination of resources and skills is highly potent: we are able to conduct the most complex studies, in patients, in a Phase I set-up.
ARENSIA is committed to enable patients the access to new therapies as early as possible.
Patient´s safety and comfort are of paramount priority at all ARENSIA clinics.
The company has strategic, exclusive partnerships with reputable university and clinical hospitals in Romania, Republic of Moldova, Lithuania and Georgia for exploratory drug development projects.
ARENSIA serves following therapeutic areas:
immuno-inflammatory, cardiovascular, diabetes/metabolic, respiratory, hepatology, nephrology, gastroenterology, infectious diseases HCV/HIV, urology, oncology, dermatology, neurology, psychiatry, ophthalmology.
ARENSIA has the expertise to perform sophisticated designs and clinical investigations/biomarkers within a scientific environment: intensive PK and PD schedules, long hospitalization, invasive and non-invasive techniques.
Latest generation imaging technology is available e.g. 3T MRI, CT, PET, etc.
The timelines for regulatory approval are reliable and competitive:
4 weeks for Moldova and Georgia, resectively 8 weeks for Romania and Lithuania.
ARENSIA has repeat business with major international Sponsors.
ARENSIA´s efficient organization and extraordinary fast recruitment speed ensures that the overall project budget can be considerably reduced, due to the fact that the number of sites to be opened can be minimized.